stockrow
Friday 6 November 2026
Export PROF’s income statement to Excel — free account
Profound Medical
PROF Healthcare Medical Devices
Profound Medical’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, up 50.7% from fiscal 2024.
- Revenue
- +85.9%
- EPS
- +18.8%
- Free cash flow
- +47.9%
- Total debt
- +0.71%
Quarter to September 2026, against a year earlier
7.12
0.24
+3.49%
Follow PROF
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 4 | 4 | 4 |
+8 more TTM periods Free account |
| (87.04%) | (73.53%) | (70.59%) | (67.12%) | ||
| (64.68%) | (58.44%) | (57.92%) | (57.64%) | ||
ROIC |
(156.58%) | (137.78%) | (174.72%) | (230.01%) | |
Return on Tangible Assets |
(75.21%) | (65.09%) | (65.26%) | (60.20%) | |
Average Days of Receivables |
169.79 | 183.86 | 182.81 | 163.25 | |
Free Cash Flow per Share |
(0.86) | (0.99) | (1.06) | (1.29) | |
Free Cash Flow |
(31.49) | (36.10) | (38.51) | (38.86) | |
Capital Expenditures |
— | — | — | (0.65) | |
| Other line items | |||||
Cash ROIC |
(39.19%) | (38.99%) | (33.71%) | (29.74%) | |
Accounts Receivable Turnover |
2.47 | 2.63 | 2.45 | 2.26 | |
Accounts Payable Turnover |
7.00 | 5.66 | 3.41 | 3.27 | |
Inventory Turnover |
0.66 | 0.57 | 0.69 | 0.67 | |
Average Days of Payables |
61.93 | 64.73 | 143.67 | 121.25 | |
Days of Inventory on Hand |
605.20 | 708.72 | 603.71 | 639.08 | |
Tax Rate |
0.00 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
88.86% | 107.96% | 111.88% | 127.94% | |
Selling, General and Administrative Expense of Revenue |
130.08% | 149.14% | 161.75% | 199.10% | |
Share Based Compensation of Revenue |
15.07% | 26.05% | 29.49% | 34.10% | |
Operating CF/Net income |
0.97 | 1.10 | 0.99 | 0.90 | |
Depreciation/Fixed assets |
1.11 | 0.88 | 0.73 | 0.80 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (1.17) | |
Revenue per Share |
0.65 | 0.53 | 0.52 | 0.53 | |
Operating CF per Share |
(0.86) | (0.99) | (1.06) | (1.26) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.04 |
Columns are period end dates · fundamentals updated 5 Nov 2026